FDA: No Monitoring Needed When Prescribing Statins

One of the most common visits in primary care may soon go away. The quarterly lipid profile and liver function check is unnecessary according to the FDA. The new guidelines have a new twist, however: There is more emphasis on the possibility of changes in cognitive function among patients taking statins.

via Press Announcements > FDA announces safety changes in labeling for some cholesterol-lowering drugs.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s